APO Research
Talk to an analyst

APO RESEARCH · REPORT

Human Vaccine Contract Manufacturing

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032

2 May 2026124 pages

Choose your research edition.

Industry ResearchHuman Vaccine Contract Manufacturing Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Human Vaccine Contract Manufacturing Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Human Vaccine Contract Manufacturing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Human Vaccine Contract Manufacturing Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Human Vaccine Contract Manufacturing Market Analysis and Forecast 2026-2032201 pages · $4,950 USD

Market perspective

According to APO Research, the global Human Vaccine Contract Manufacturing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Human Vaccine Contract Manufacturing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Human Vaccine Contract Manufacturing market include Lonza, Fujifilm Diosynth Biotechnologies U.S.A., Inc., Ajinomoto Althea, Inc., Merck KgaA, Cytovance Biologics, Catalent, Inc., IDT Biologika GmbH, Albany Molecular Research, Inc. and PRA Health Sciences, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Human Vaccine Contract Manufacturing market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Human Vaccine Contract Manufacturing market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Human Vaccine Contract Manufacturing market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Human Vaccine Contract Manufacturing.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Human Vaccine Contract Manufacturing market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Human Vaccine Contract Manufacturing Market by Company

Lonza

Fujifilm Diosynth Biotechnologies U.S.A., Inc.

Ajinomoto Althea, Inc.

Merck KgaA

Cytovance Biologics

Catalent, Inc.

IDT Biologika GmbH

Albany Molecular Research, Inc.

PRA Health Sciences

ICON plc.

Pharmaceutical Product Development, LLC

Cobra Bio

Paragon Bioservices, Inc.

Emergent BioSolutions Inc.

CSL Limited

BioNTech SE

Wuxi Biologics

Samsung Biologics

Boehringer Ingelheim

Novavax, Inc.

Human Vaccine Contract Manufacturing Segment by Type

Attenuated

Inactivated

Subunit-based

Toxoid-based

DNA-based

Human Vaccine Contract Manufacturing Segment by Application

Downstream

Upstream

Human Vaccine Contract Manufacturing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Vaccine Contract Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Human Vaccine Contract Manufacturing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Vaccine Contract Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Human Vaccine Contract Manufacturing companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Human Vaccine Contract Manufacturing Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Human Vaccine Contract Manufacturing Market Share by Region (2021-2026) Table 4. Global Human Vaccine Contract Manufacturing Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Human Vaccine Contract Manufacturing Market Share by Region (2027-2032) Table 6. Global Human Vaccine Contract Manufacturing Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Human Vaccine Contract Manufacturing Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2026) Table 9. Global Human Vaccine Contract Manufacturing Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Human Vaccine Contract Manufacturing Market Size Share Forecasted by Type (2027-2032) Table 11. North America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Human Vaccine Contract Manufacturing Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Human Vaccine Contract Manufacturing Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2026) Table 24. Global Human Vaccine Contract Manufacturing Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Human Vaccine Contract Manufacturing Market Size Share Forecasted by Application (2027-2032) Table 26. North America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Human Vaccine Contract Manufacturing Industry Trends Table 37. Human Vaccine Contract Manufacturing Industry Drivers Table 38. Human Vaccine Contract Manufacturing Industry Opportunities and Challenges Table 39. Human Vaccine Contract Manufacturing Industry Restraints Table 40. Global Human Vaccine Contract Manufacturing Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Human Vaccine Contract Manufacturing Revenue Market Share by Company (2021-2026) Table 42. Global Human Vaccine Contract Manufacturing Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Human Vaccine Contract Manufacturing Key Company Headquarters & Area Served Table 44. Global Human Vaccine Contract Manufacturing Company, Product Type & Application Table 45. Global Human Vaccine Contract Manufacturing Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Human Vaccine Contract Manufacturing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Lonza Company Information Table 49. Lonza Business Overview Table 50. Lonza Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Lonza Human Vaccine Contract Manufacturing Product Portfolio Table 52. Lonza Recent Development Table 53. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information Table 54. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview Table 55. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 57. Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Development Table 58. Ajinomoto Althea, Inc. Company Information Table 59. Ajinomoto Althea, Inc. Business Overview Table 60. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 62. Ajinomoto Althea, Inc. Recent Development Table 63. Merck KgaA Company Information Table 64. Merck KgaA Business Overview Table 65. Merck KgaA Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio Table 67. Merck KgaA Recent Development Table 68. Cytovance Biologics Company Information Table 69. Cytovance Biologics Business Overview Table 70. Cytovance Biologics Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 72. Cytovance Biologics Recent Development Table 73. Catalent, Inc. Company Information Table 74. Catalent, Inc. Business Overview Table 75. Catalent, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 77. Catalent, Inc. Recent Development Table 78. IDT Biologika GmbH Company Information Table 79. IDT Biologika GmbH Business Overview Table 80. IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio Table 82. IDT Biologika GmbH Recent Development Table 83. Albany Molecular Research, Inc. Company Information Table 84. Albany Molecular Research, Inc. Business Overview Table 85. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 87. Albany Molecular Research, Inc. Recent Development Table 88. PRA Health Sciences Company Information Table 89. PRA Health Sciences Business Overview Table 90. PRA Health Sciences Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio Table 92. PRA Health Sciences Recent Development Table 93. ICON plc. Company Information Table 94. ICON plc. Business Overview Table 95. ICON plc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. ICON plc. Human Vaccine Contract Manufacturing Product Portfolio Table 97. ICON plc. Recent Development Table 98. Pharmaceutical Product Development, LLC Company Information Table 99. Pharmaceutical Product Development, LLC Business Overview Table 100. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio Table 102. Pharmaceutical Product Development, LLC Recent Development Table 103. Cobra Bio Company Information Table 104. Cobra Bio Business Overview Table 105. Cobra Bio Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio Table 107. Cobra Bio Recent Development Table 108. Paragon Bioservices, Inc. Company Information Table 109. Paragon Bioservices, Inc. Business Overview Table 110. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 112. Paragon Bioservices, Inc. Recent Development Table 113. Emergent BioSolutions Inc. Company Information Table 114. Emergent BioSolutions Inc. Business Overview Table 115. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 117. Emergent BioSolutions Inc. Recent Development Table 118. CSL Limited Company Information Table 119. CSL Limited Business Overview Table 120. CSL Limited Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. CSL Limited Human Vaccine Contract Manufacturing Product Portfolio Table 122. CSL Limited Recent Development Table 123. BioNTech SE Company Information Table 124. BioNTech SE Business Overview Table 125. BioNTech SE Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio Table 127. BioNTech SE Recent Development Table 128. Wuxi Biologics Company Information Table 129. Wuxi Biologics Business Overview Table 130. Wuxi Biologics Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 132. Wuxi Biologics Recent Development Table 133. Samsung Biologics Company Information Table 134. Samsung Biologics Business Overview Table 135. Samsung Biologics Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio Table 137. Samsung Biologics Recent Development Table 138. Boehringer Ingelheim Company Information Table 139. Boehringer Ingelheim Business Overview Table 140. Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio Table 142. Boehringer Ingelheim Recent Development Table 143. Novavax, Inc. Company Information Table 144. Novavax, Inc. Business Overview Table 145. Novavax, Inc. Human Vaccine Contract Manufacturing Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio Table 147. Novavax, Inc. Recent Development Table 148. North America Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Human Vaccine Contract Manufacturing Market Share by Country (2021-2026) Table 151. North America Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Human Vaccine Contract Manufacturing Market Share Forecast by Country (2027-2032) Table 153. Europe Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Human Vaccine Contract Manufacturing Market Share by Country (2021-2026) Table 156. Europe Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Human Vaccine Contract Manufacturing Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Human Vaccine Contract Manufacturing Market Share by Country (2021-2026) Table 161. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Human Vaccine Contract Manufacturing Market Share Forecast by Country (2027-2032) Table 163. Latin America Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Human Vaccine Contract Manufacturing Market Share by Country (2021-2026) Table 166. Latin America Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Human Vaccine Contract Manufacturing Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country (2021-2026) Table 171. Middle East & Africa Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Human Vaccine Contract Manufacturing Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Human Vaccine Contract Manufacturing Product Image Figure 3. Global Human Vaccine Contract Manufacturing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Human Vaccine Contract Manufacturing Market Size (2021-2032) & (US$ Million) Figure 5. Global Human Vaccine Contract Manufacturing Market Share by Region: 2025 VS 2032 Figure 6. Global Human Vaccine Contract Manufacturing Market Share by Region (2021-2032) Figure 7. North America Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Attenuated Image Figure 13. Global Attenuated Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Inactivated Image Figure 15. Global Inactivated Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Subunit-based Image Figure 17. Global Subunit-based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Toxoid-based Image Figure 19. Global Toxoid-based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. DNA-based Image Figure 21. Global DNA-based Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. Global Human Vaccine Contract Manufacturing Market Size Overview by Type (2021-2032) & (US$ Million) Figure 23. Global Human Vaccine Contract Manufacturing Market Share by Type 2025 VS 2032 Figure 24. North America Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032) Figure 25. Europe Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032) Figure 26. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032) Figure 27. Latin America Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032) Figure 28. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Share by Type (2021-2032) Figure 29. Downstream Image Figure 30. Global Downstream Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Upstream Image Figure 32. Global Upstream Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Human Vaccine Contract Manufacturing Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Human Vaccine Contract Manufacturing Market Share by Application 2025 VS 2032 Figure 35. North America Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032) Figure 36. Europe Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032) Figure 38. Latin America Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Human Vaccine Contract Manufacturing Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Human Vaccine Contract Manufacturing Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Human Vaccine Contract Manufacturing Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Human Vaccine Contract Manufacturing Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 45. Europe Human Vaccine Contract Manufacturing Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Human Vaccine Contract Manufacturing Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 48. Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Human Vaccine Contract Manufacturing Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 51. Latin America Human Vaccine Contract Manufacturing Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Human Vaccine Contract Manufacturing Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 54. Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Human Vaccine Contract Manufacturing Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based
Applications
  • Downstream
  • Upstream
Companies covered
  • Lonza
  • Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  • Ajinomoto Althea, Inc.
  • Merck KgaA
  • Cytovance Biologics
  • Catalent, Inc.
  • IDT Biologika GmbH
  • Albany Molecular Research, Inc.
  • PRA Health Sciences
  • ICON plc.
  • Pharmaceutical Product Development, LLC
  • Cobra Bio
  • Paragon Bioservices, Inc.
  • Emergent BioSolutions Inc.
  • CSL Limited
  • BioNTech SE
  • Wuxi Biologics
  • Samsung Biologics
  • Boehringer Ingelheim
  • Novavax, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Human Vaccine Contract Manufacturing Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2032)
  5. 1.4.1 Global Human Vaccine Contract Manufacturing Market Size by Region (2021-2026)
  6. 1.4.2 Global Human Vaccine Contract Manufacturing Market Size by Region (2027-2032)
  7. 1.5 Key Regions Human Vaccine Contract Manufacturing Market Size (2021-2032)
  8. 1.5.1 North America Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Human Vaccine Contract Manufacturing Market Size Growth Rate (2021-2032)
2 Human Vaccine Contract Manufacturing Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Attenuated
  3. 2.1.2 Inactivated
  4. 2.1.3 Subunit-based
  5. 2.1.4 Toxoid-based
  6. 2.1.5 DNA-based
  7. 2.2 Global Human Vaccine Contract Manufacturing Market Size by Type
  8. 2.2.1 Global Human Vaccine Contract Manufacturing Market Size Overview by Type (2021-2032)
  9. 2.2.2 Global Human Vaccine Contract Manufacturing Historic Market Size Review by Type (2021-2026)
  10. 2.2.3 Global Human Vaccine Contract Manufacturing Market Size Forecasted by Type (2027-2032)
  11. 2.3 Global Human Vaccine Contract Manufacturing Market Size by Regions
  12. 2.3.1 North America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026)
  13. 2.3.2 Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026)
  14. 2.3.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026)
  15. 2.3.4 South America Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026)
  16. 2.3.5 Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Type (2021-2026)
3 Human Vaccine Contract Manufacturing Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Downstream
  3. 3.1.2 Upstream
  4. 3.2 Global Human Vaccine Contract Manufacturing Market Size by Application
  5. 3.2.1 Global Human Vaccine Contract Manufacturing Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Human Vaccine Contract Manufacturing Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Human Vaccine Contract Manufacturing Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Human Vaccine Contract Manufacturing Market Size by Regions
  9. 3.3.1 North America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Human Vaccine Contract Manufacturing Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Human Vaccine Contract Manufacturing Industry Trends
  2. 4.2 Human Vaccine Contract Manufacturing Industry Drivers
  3. 4.3 Human Vaccine Contract Manufacturing Industry Opportunities and Challenges
  4. 4.4 Human Vaccine Contract Manufacturing Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Human Vaccine Contract Manufacturing Revenue (2021-2026)
  2. 5.2 Global Human Vaccine Contract Manufacturing Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Human Vaccine Contract Manufacturing Key Company Headquarters & Area Served
  4. 5.4 Global Human Vaccine Contract Manufacturing Company, Product Type & Application
  5. 5.5 Global Human Vaccine Contract Manufacturing Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Human Vaccine Contract Manufacturing Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Human Vaccine Contract Manufacturing Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Human Vaccine Contract Manufacturing Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Lonza
  2. 6.1.1 Lonza Company Information
  3. 6.1.2 Lonza Business Overview
  4. 6.1.3 Lonza Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Lonza Human Vaccine Contract Manufacturing Product Portfolio
  6. 6.1.5 Lonza Recent Developments
  7. 6.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc.
  8. 6.2.1 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Company Information
  9. 6.2.2 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Business Overview
  10. 6.2.3 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Human Vaccine Contract Manufacturing Product Portfolio
  12. 6.2.5 Fujifilm Diosynth Biotechnologies U.S.A., Inc. Recent Developments
  13. 6.3 Ajinomoto Althea, Inc.
  14. 6.3.1 Ajinomoto Althea, Inc. Company Information
  15. 6.3.2 Ajinomoto Althea, Inc. Business Overview
  16. 6.3.3 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Ajinomoto Althea, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  18. 6.3.5 Ajinomoto Althea, Inc. Recent Developments
  19. 6.4 Merck KgaA
  20. 6.4.1 Merck KgaA Company Information
  21. 6.4.2 Merck KgaA Business Overview
  22. 6.4.3 Merck KgaA Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Merck KgaA Human Vaccine Contract Manufacturing Product Portfolio
  24. 6.4.5 Merck KgaA Recent Developments
  25. 6.5 Cytovance Biologics
  26. 6.5.1 Cytovance Biologics Company Information
  27. 6.5.2 Cytovance Biologics Business Overview
  28. 6.5.3 Cytovance Biologics Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Cytovance Biologics Human Vaccine Contract Manufacturing Product Portfolio
  30. 6.5.5 Cytovance Biologics Recent Developments
  31. 6.6 Catalent, Inc.
  32. 6.6.1 Catalent, Inc. Company Information
  33. 6.6.2 Catalent, Inc. Business Overview
  34. 6.6.3 Catalent, Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Catalent, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  36. 6.6.5 Catalent, Inc. Recent Developments
  37. 6.7 IDT Biologika GmbH
  38. 6.7.1 IDT Biologika GmbH Company Information
  39. 6.7.2 IDT Biologika GmbH Business Overview
  40. 6.7.3 IDT Biologika GmbH Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 IDT Biologika GmbH Human Vaccine Contract Manufacturing Product Portfolio
  42. 6.7.5 IDT Biologika GmbH Recent Developments
  43. 6.8 Albany Molecular Research, Inc.
  44. 6.8.1 Albany Molecular Research, Inc. Company Information
  45. 6.8.2 Albany Molecular Research, Inc. Business Overview
  46. 6.8.3 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Albany Molecular Research, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  48. 6.8.5 Albany Molecular Research, Inc. Recent Developments
  49. 6.9 PRA Health Sciences
  50. 6.9.1 PRA Health Sciences Company Information
  51. 6.9.2 PRA Health Sciences Business Overview
  52. 6.9.3 PRA Health Sciences Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 PRA Health Sciences Human Vaccine Contract Manufacturing Product Portfolio
  54. 6.9.5 PRA Health Sciences Recent Developments
  55. 6.10 ICON plc.
  56. 6.10.1 ICON plc. Company Information
  57. 6.10.2 ICON plc. Business Overview
  58. 6.10.3 ICON plc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 ICON plc. Human Vaccine Contract Manufacturing Product Portfolio
  60. 6.10.5 ICON plc. Recent Developments
  61. 6.11 Pharmaceutical Product Development, LLC
  62. 6.11.1 Pharmaceutical Product Development, LLC Company Information
  63. 6.11.2 Pharmaceutical Product Development, LLC Business Overview
  64. 6.11.3 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Pharmaceutical Product Development, LLC Human Vaccine Contract Manufacturing Product Portfolio
  66. 6.11.5 Pharmaceutical Product Development, LLC Recent Developments
  67. 6.12 Cobra Bio
  68. 6.12.1 Cobra Bio Company Information
  69. 6.12.2 Cobra Bio Business Overview
  70. 6.12.3 Cobra Bio Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Cobra Bio Human Vaccine Contract Manufacturing Product Portfolio
  72. 6.12.5 Cobra Bio Recent Developments
  73. 6.13 Paragon Bioservices, Inc.
  74. 6.13.1 Paragon Bioservices, Inc. Company Information
  75. 6.13.2 Paragon Bioservices, Inc. Business Overview
  76. 6.13.3 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Paragon Bioservices, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  78. 6.13.5 Paragon Bioservices, Inc. Recent Developments
  79. 6.14 Emergent BioSolutions Inc.
  80. 6.14.1 Emergent BioSolutions Inc. Company Information
  81. 6.14.2 Emergent BioSolutions Inc. Business Overview
  82. 6.14.3 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Emergent BioSolutions Inc. Human Vaccine Contract Manufacturing Product Portfolio
  84. 6.14.5 Emergent BioSolutions Inc. Recent Developments
  85. 6.15 CSL Limited
  86. 6.15.1 CSL Limited Company Information
  87. 6.15.2 CSL Limited Business Overview
  88. 6.15.3 CSL Limited Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 CSL Limited Human Vaccine Contract Manufacturing Product Portfolio
  90. 6.15.5 CSL Limited Recent Developments
  91. 6.16 BioNTech SE
  92. 6.16.1 BioNTech SE Company Information
  93. 6.16.2 BioNTech SE Business Overview
  94. 6.16.3 BioNTech SE Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 BioNTech SE Human Vaccine Contract Manufacturing Product Portfolio
  96. 6.16.5 BioNTech SE Recent Developments
  97. 6.17 Wuxi Biologics
  98. 6.17.1 Wuxi Biologics Company Information
  99. 6.17.2 Wuxi Biologics Business Overview
  100. 6.17.3 Wuxi Biologics Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Wuxi Biologics Human Vaccine Contract Manufacturing Product Portfolio
  102. 6.17.5 Wuxi Biologics Recent Developments
  103. 6.18 Samsung Biologics
  104. 6.18.1 Samsung Biologics Company Information
  105. 6.18.2 Samsung Biologics Business Overview
  106. 6.18.3 Samsung Biologics Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 Samsung Biologics Human Vaccine Contract Manufacturing Product Portfolio
  108. 6.18.5 Samsung Biologics Recent Developments
  109. 6.19 Boehringer Ingelheim
  110. 6.19.1 Boehringer Ingelheim Company Information
  111. 6.19.2 Boehringer Ingelheim Business Overview
  112. 6.19.3 Boehringer Ingelheim Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Boehringer Ingelheim Human Vaccine Contract Manufacturing Product Portfolio
  114. 6.19.5 Boehringer Ingelheim Recent Developments
  115. 6.20 Novavax, Inc.
  116. 6.20.1 Novavax, Inc. Company Information
  117. 6.20.2 Novavax, Inc. Business Overview
  118. 6.20.3 Novavax, Inc. Human Vaccine Contract Manufacturing Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Novavax, Inc. Human Vaccine Contract Manufacturing Product Portfolio
  120. 6.20.5 Novavax, Inc. Recent Developments
7 North America
  1. 7.1 North America Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  3. 7.3 North America Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  3. 8.3 Europe Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  3. 10.3 South America Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Human Vaccine Contract Manufacturing Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Human Vaccine Contract Manufacturing Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Human Vaccine Contract Manufacturing Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst